NASDAQ:CDT CDT Equity Q2 2026 Earnings Report $0.99 -0.26 (-20.80%) Closing price 10/2/2026 04:00 PM EasternExtended Trading$0.96 -0.03 (-3.43%) As of 10/2/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast CDT Equity EPS ResultsActual EPS-$217.75Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/ACDT Equity Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ACDT Equity Announcement DetailsQuarterQ2 2026Date8/12/2026TimeAfter Market ClosesConference Call DateN/AConference Call TimeN/AConference Call ResourcesEarnings HistoryCompany Profile CDT Equity Earnings HeadlinesCDT Highlights Sarborg’s Expanding Quantum Computing IP Portfolio and Application to Drug DiscoverySeptember 29, 2026 | finance.yahoo.comCDT Equity Inc.: CDT Highlights Sarborg's Expanding Quantum Computing IP Portfolio and Application to Drug DiscoverySeptember 29, 2026 | finanznachrichten.deThe REAL Reason Trump is Invading IranFor a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Because my research has led me to believe we’re risking World War 3 with Iran for a completely different reason.October 3 at 1:00 AM | Banyan Hill Publishing (Ad)CDT Highlights Sarborg's Expanding Quantum Computing IP Portfolio and Application to Drug DiscoverySeptember 29, 2026 | globenewswire.comCDT Equity Board Approves 1-For-25 Reverse Stock Split, Pre-market Shares DownSeptember 26, 2026 | rttnews.comCDT Announces 1-for-25 Reverse Stock Split To Meet Nasdaq Compliance; Pre-market Stock PlungesSeptember 26, 2026 | rttnews.comSee More CDT Equity Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like CDT Equity? Sign up for Earnings360's daily newsletter to receive timely earnings updates on CDT Equity and other key companies, straight to your email. Email Address About CDT EquityCDT Equity (NASDAQ:CDT), Inc., traded on the Nasdaq under the symbol CDT, is associated with Conduit Pharmaceuticals, a clinical-stage biopharmaceutical company focused on developing treatments for serious autoimmune and inflammatory diseases. The company’s business model centers on acquiring and advancing clinical-stage drug candidates through partnerships with academic institutions and pharmaceutical companies. Its portfolio has included investigational therapies intended to address conditions such as systemic sclerosis and other immune-mediated diseases, although the status and composition of its development programs may change as clinical and corporate activities progress. Conduit Pharmaceuticals was established to help translate externally developed drug candidates into commercial medicines. Publicly available information about CDT Equity’s current operating structure, leadership, and geographic activities is limited.View CDT Equity ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 09/28 - 10/02Time to Nibble on MCD Stock After it Enters Oversold Territory?McCormick Stock Trades Cheap, Offers Dividend Growth and Unilever Deal UpsideMicron’s Earnings Reveal Why the AI Memory Boom May Last LongerAnthropic's IPO Could Put Amazon's and Alphabet's Paper Profits to the TestBoeing’s Fighter Victory Opens the Door to Decades of Defense RevenueCorning and AT&T's $3 Billion Fiber Deal Reveals Where AI Spending Goes Next Upcoming Earnings PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
